Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
Recruiting
Phase 2
Interventional Study
Hodgkin Lymphoma, Adult
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 54 (estimated)
- Sponsor
- National Medical Research Radiological Centre of the Ministry of Health of Russia · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The aim of the current trial is to evaluate the efficacy and safety of flat-dose nivolumab (40 mg) in combination with AVD in the management of patients with newly diagnosed advanced classic Hodgkin Lymphoma
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Newly-diagnosed histologically verified advanced stage (IIB-IV as per GHSG) classic Hodgkin lymphoma
2. No past history of autoimmune disease
3. Age \> 18 years
4. Ejection fraction \> 50%
5. ECOG 0-4
Exclusion Criteria:
1. Organ failure (e.g. creatinine \> 2x ULN; ALT or A…
Contacts